ArticleJournal of the American Chemical Society2019
Arsenoplatin-1 Is a Dual Pharmacophore Anticancer Agent.
Article in Journal of the American Chemical Society, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 48 citations in OpenAlex.
- Redesign of the Ferritin Ferroxidase Center for Universal Molecular Binding or Specific Recognition.Small (Weinheim an der Bergstrasse, Germany) · 2026Article
- Critical re-evaluation of experimental settings with fluorescent probes for bioorthogonal chemistry with palladium antimony inactivation-resistant catalyst.Scientific reports · 2026Article
- The arsenic proteome in cancer: Unravelling molecular mechanisms of anticancer drugs.Journal of biological inorganic chemistry : JBIC : a publication of the Society of Biological Inorganic Chemistry · 2026Review
- The Effect of pH during Fabrication of Platinum-Containing Polymeric Arsenical Hydrogels.Macromolecules · 2025Article
- A Tunable Hydrogel Platform Based on Platinum-Containing Polymeric Arsenicals.Chemistry of materials : a publication of the American Chemical Society · 2025Article
- Description of a Non-Canonical AsPt Blue Species Originating from the Aerobic Oxidation of AP-1 in Aqueous Solution.International journal of molecular sciences · 2024Article
- Radiochemistry: A Hot Field with Opportunities for Cool Chemistry.ACS central science · 2023Review
- Arsenic in medicine: past, present and future.Biometals : an international journal on the role of metal ions in biology, biochemistry, and medicine · 2023Review
- Metallodrugs: Mechanisms of Action, Molecular Targets and Biological Activity.International journal of molecular sciences · 2022Article
- Reactions of Arsenoplatin-1 with Protein Targets: A Combined Experimental and Theoretical Study.Inorganic chemistry · 2022Article
- Can polyoxometalates (POMs) prevent of coronavirus 2019-nCoV cell entry? Interaction of POMs with TMPRSS2 and spike receptor domain complexed with ACE2 (ACE2-RBD): Virtual screening approaches.Informatics in medicine unlocked · 2022Article
- Spectroscopic/Computational Characterization and the X-ray Structure of the Adduct of the VInorganic chemistry · 2021Article
- In Vitro Anti-SARS-CoV-2 Activity of Selected Metal Compounds and Potential Molecular Basis for Their Actions Based on Computational Study.Biomolecules · 2021Article
- Iodide Analogs of Arsenoplatins-Potential Drug Candidates for Triple Negative Breast Cancers.Molecules (Basel, Switzerland) · 2021Article
- Strategies for the Improvement of Metal-Based Chemotherapeutic Treatments.Biomedicines · 2021Review
- Arsenoplatin-Ferritin Nanocage: Structure and Cytotoxicity.International journal of molecular sciences · 2021Article
- An anticancer gold(III)-activated porphyrin scaffold that covalently modifies protein cysteine thiols.Proceedings of the National Academy of Sciences of the United States of America · 2020Article
- Beyond Cisplatin: Combination Therapy with Arsenic Trioxide.Inorganica chimica acta · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 5 institutions in 2 countries.
Funding
Abstract
Arsenoplatins are adducts of two chemically important anticancer drugs, cisplatin and arsenic trioxide, that have a Pt(II) bond to an As(III) hydroxide center. Screens of the NCI-60 human tumor cell lines reveal that arsenoplatin-1 (AP-1), [Pt(μ-NHC(CH
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.